{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024985","form_type":"8-K","ticker":null,"cik":"0001814140","company_name":"Apexigen, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.266872+00:00","generated_at":"2026-06-21T21:00:25.021282+00:00","sec_items":["4.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apexigen reports positive Phase 2 data for sotigalimab in liposarcoma; mPFS 12.45 mo","bullets":["Sotigalimab + doxorubicin achieved median PFS of 12.45 months in liposarcoma patients vs historical <5 months for doxorubicin alone.","Apexigen plans to expand LPS cohort by 10 patients to inform potential Phase 3 registration-enabling trial.","Favorable safety profile observed; data supports further development in first-line liposarcoma.","Study is investigator-sponsored trial in collaboration with Columbia University (Gary Schwartz, PI)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024985","json":"https://secwatch.observer/filing/0000950170-22-024985.json","markdown":"https://secwatch.observer/filing/0000950170-22-024985.md","text":"https://secwatch.observer/filing/0000950170-22-024985.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1814140/000095017022024985/0000950170-22-024985-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1814140/000095017022024985/apgn-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:00:25.021282+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68828e417bc0d3ba084939d48960caf50682e72d","claim":"Apexigen, Inc. engaged Moss Adams LLP as its auditor.","evidence_excerpt":"On November 8, 2022, the Audit Committee approved the engagement of Moss Adams LLP as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ending December 31, 2022.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1814140/000095017022024985/0000950170-22-024985-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Moss Adams LLP"}],"fact_type":"auditor_change"},{"claim_id":"f12e777eb76ca4374f5d73c4227d5460b7519837","claim":"Apexigen, Inc. dismissed Marcum LLP as its auditor.","evidence_excerpt":"On November 8, 2022, the audit committee of the board of directors (the “Audit Committee”) of Apexigen, Inc. (the “Company”), dismissed Marcum LLP (“Marcum”), the Company’s independent registered public accounting firm prior to the Company’s business combination transaction that closed on July 29, 2022 (the “Business Combination”).","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1814140/000095017022024985/0000950170-22-024985-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"Marcum LLP"},{"label":"Successor","value":"Moss Adams LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}